Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
(9 sites) United States
USC/Norris Comprehensive Cancer Center, Los Angeles, California Yale University Cancer Center, New Haven, Connecticut The Winship Cancer Institute Emory University, Atlanta, Georgia START Midwest, Grand Rapids, Michigan Memorial Sloan Kettering Cancer Center, New York, New York Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania SCRI, Nashville, Tennessee MD Anderson Cancer Center, Houston, Texas Virginia Cancer Specialists, Fairfax, Virginia